Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
about
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewHallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients.Assessing dynamic brain graphs of time-varying connectivity in fMRI data: application to healthy controls and patients with schizophrenia.Effect of antipsychotic pharmacotherapy on clinical outcomes of intermittent theta-burst stimulation for refractory depression.Cortical thinning, functional connectivity, and mood-related impulsivity in schizophrenia: relationship to aggressive attitudes and behavior.Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients.Atypical antipsychotics as augmentation therapy in anorexia nervosa.The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service.Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders"Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose MethodVerbal memory impairments in schizophrenia associated with cortical thinningAssociation between antipsychotic/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case registerAssociation of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk.Dose Equivalents for Antipsychotic Drugs: The DDD MethodPsychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUSResting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia.Preliminary Study on Quantitative Sleep EEG Characteristics in Patients with Schizophrenia.Cognitive training of self-initiation of semantic encoding strategies in schizophrenia: A pilot study.A case for motor network contributions to schizophrenia symptoms: Evidence from resting-state connectivity.Cariprazine for the Treatment of Bipolar Disorder.Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy.Halting Antipsychotic Use in Long-Term care (HALT): a single-arm longitudinal study aiming to reduce inappropriate antipsychotic use in long-term care residents with behavioral and psychological symptoms of dementia.Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.Disturbances of Agency and Ownership in Schizophrenia: An Auditory Verbal Event Related Potentials Study.Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.Comparative risk of oral ulcerations among antipsychotics users - population-based retrospective cohort study.Probabilistic Reversal Learning in Schizophrenia: Stability of Deficits and Potential Causal Mechanisms.TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical triCognitive deficits characterization using the CogState Research Battery in first-episode psychosis patients.Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.The aprosody of schizophrenia: Computationally derived acoustic phonetic underpinnings of monotone speech.Prevalence and correlates of diabetes mellitus and dyslipidaemia in a long-stay inpatient schizophrenia population in Singapore.Metacognition as a Mediating Variable Between Neurocognition and Functional Outcome in First Episode Psychosis.Improving the physical health of long-term psychiatric inpatients.History of Suicide Attempt Is Associated with Reduced Medial Prefrontal Cortex Activity during Emotional Decision-Making among Men with Schizophrenia: An Exploratory fMRI Study.
P2860
Q28079821-0E3AD402-B3C2-4739-9EA3-329676425B1AQ30367997-A3B8CD82-5C0C-4662-A43D-45B0FFB2AC6DQ30878845-3858161D-6AE8-407F-BFF7-997500AF123AQ31142701-06849550-C017-4234-8837-C805DF8C812FQ34262520-3A980B31-205B-4244-A172-0FD0F2112B6FQ35108892-C8439732-C78D-41EC-80A6-52FC13437F19Q35553293-FAEE6B22-FB92-4E57-94A4-D55914F13254Q35825226-F3C5312B-BDA4-445D-A7C6-25BB9252C024Q35941992-DB3042D9-F778-47E1-94A7-7E33CB065BD1Q36148481-99EAEE96-FA7E-4D6F-9750-59ACEF3ECAC6Q36518199-5DA0D4C7-414C-48EB-8D34-8CACB7009743Q36848311-C4C97F0E-732A-499C-9D68-EEC0B88B3433Q36968057-8FECCD84-82C0-4966-967B-130767F3B954Q37124935-EDF7A5DF-0898-4B68-9FF6-9BF554AE99C4Q37124952-2C2D95B4-8FA0-45CE-B622-AD24C5837461Q37582371-1FE67B1E-404A-4DB2-9CBC-FCE63444E553Q37641485-F9C89A0D-E220-4621-B357-0F800A0BE1D9Q37706446-2500E626-22BD-4C75-B253-D20DD21F2B6CQ38408659-23977FB8-13E3-4485-BF7E-22FB1015CE7EQ38730897-3C4E3CE7-0BC1-4DB0-9F47-FD79B8235618Q38802226-2AB15BA6-7976-4072-9426-30B4BD3C4DF9Q38834502-0BF45C0B-A10C-4EA8-AE22-5E55010292FBQ38925563-D6EE50A7-7C16-4E4F-AD9F-49C9F5B2C65EQ38948958-58A93A3C-A255-4859-B43D-16E3B14A1140Q39746778-5732EB6A-1787-4B44-A738-22D2200798CDQ41078160-74F75567-AF73-4554-9D52-1DBDE20E606EQ41139776-54A8FA70-9E58-4002-A53E-8D4948CE2D76Q41880175-CD150D99-926A-47EE-9479-B3ACF6E92191Q42031334-BE6637E0-2611-4E5A-965B-F13470E00745Q47550663-5E696EE0-F136-4804-9835-B31E39F1F663Q47998008-66EB80D5-0C2E-46FC-8C58-BA3C92A6563FQ48417176-53DAC387-99E2-4435-8B08-D9C8249540C5Q49962407-5292D549-A5DE-4C60-BD07-F4D227DC8440Q50072228-8D341596-7FA0-4F23-BAD5-68E8969AD0F7Q50159065-57DC541C-7308-4F5E-B9BF-264B967E6DE0Q50644723-9CAA8282-3762-4C2D-99BE-AD07738D848CQ55093508-33261AA5-9F4C-48BE-8F2A-86DFF5D6B6D6
P2860
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@en
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@nl
type
label
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@en
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@nl
prefLabel
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@en
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@nl
P2093
P2860
P356
P1476
Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
@en
P2093
John M Davis
Maxine X Patel
Myrto Samara
Scott W Woods
Stefan Leucht
Stephan Heres
P2860
P304
P356
10.1093/SCHBUL/SBU001
P407
P577
2014-02-03T00:00:00Z